ログイン
言語:

WEKO3

  • トップ
  • コミュニティ
  • ランキング
AND
To

Field does not validate



インデックスリンク

インデックスツリー

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "ee9afa12-7dc1-4f4c-a4f7-3b0caa26ef91"}, "_deposit": {"id": "3767", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "3767"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00003767"}, "item_6_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2013-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "509", "bibliographicPageStart": "506", "bibliographicVolumeNumber": "18", "bibliographic_titles": [{"bibliographic_title": "INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY"}]}]}, "item_6_description_20": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "Because metastatic cutaneous squamous cell carcinoma (CSCC) is rare, standard chemotherapy has not been fully established. In Japan, combination platinum and anthracycline chemotherapy has been used for elderly patients with advanced CSCC because of its low toxicity. However, the clinical benefit of this therapy has not been fully examined. We retrospectively examined the response rate of combination platinum and anthracycline chemotherapy for metastatic CSCC. Eight patients received combination chemotherapy for metastatic lesions; there were lymph node lesions in 6 patients and skin and lung lesions in one patient each. The combination regimens were as follows: cisplatin (CDDP) (60-90 mg/m(2)/day, day 1) and adriamycin (ADM) (20-40 mg/m(2)/day, day 1 or 2) was administered in 5 patients; CDDP (10-15 mg/m(2)/day, days 1-5) and epirubicin (epi-ADM) (10-15 mg/m(2)/day, days 1-5) was administered in 2 patients; and carboplatin (CBDCA) (200-400 mg/m(2)/day, day 1) and ADM (20-40 mg/m(2)/day, day 1 or 2) was administered in one patient. The responses were as follows: complete response in 2 patients (CDDP + ADM for lung metastasis, CDDP + epi-ADM for lymph node metastasis), partial response in 1 (CDDP + ADM for lymph node metastasis), stable disease in 2, and progressive disease in 3. A durable response was observed in 2 patients showing complete responses (58 and 112 months). The clinical effect of the combination of platinum and anthracycline for metastatic CSCC was limited despite the findings of two patients showing durable complete responses.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7\uff08\u30b3\u30f3\u30c6\u30f3\u30c4\u306e\u7a2e\u985e\uff09", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "\u5f15\u7528", "attribute_value_mlt": [{"subitem_description": "INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 18(3):506-509 (2013)", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "\u4fe1\u5dde\u5927\u5b66\u7814\u7a76\u8005\u7dcf\u89a7\u3078\u306e\u30ea\u30f3\u30af", "attribute_value_mlt": [{"subitem_link_text": "Okuyama, Ryuhei", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.ZpfNHFSF.html"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000320456500022"}]}, "item_6_publisher_4": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "SPRINGER JAPAN KK"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "22534799"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search\u0026DB=pubmed\u0026term=22534799", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1007/s10147-012-0411-y"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://dx.doi.org/10.1007/s10147-012-0411-y", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_62": {"attribute_name": "\u6a29\u5229", "attribute_value_mlt": [{"subitem_rights": "The original publication is available at www.springerlink.com"}]}, "item_6_select_64": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1341-9625", "subitem_source_identifier_type": "ISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1341-9625", "subitem_source_identifier_type": "ISSN"}]}, "item_6_source_id_40": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AA11086579", "subitem_source_identifier_type": "NCID"}]}, "item_6_text_69": {"attribute_name": "wosonly authkey", "attribute_value_mlt": [{"subitem_text_value": "Chemotherapy; Cutaneous squamous cell carcinoma; Skin cancer; Platinum; Anthracycline"}]}, "item_6_text_70": {"attribute_name": "wosonly keywords", "attribute_value_mlt": [{"subitem_text_value": "SKIN-CANCER; PHASE-II; CISPLATIN; 5-FLUOROURACIL; UPDATE; JAPAN; ACID"}]}, "item_6_textarea_68": {"attribute_name": "wosonly abstract", "attribute_value_mlt": [{"subitem_textarea_value": "Because metastatic cutaneous squamous cell carcinoma (CSCC) is rare, standard chemotherapy has not been fully established. In Japan, combination platinum and anthracycline chemotherapy has been used for elderly patients with advanced CSCC because of its low toxicity. However, the clinical benefit of this therapy has not been fully examined. We retrospectively examined the response rate of combination platinum and anthracycline chemotherapy for metastatic CSCC. Eight patients received combination chemotherapy for metastatic lesions; there were lymph node lesions in 6 patients and skin and lung lesions in one patient each. The combination regimens were as follows: cisplatin (CDDP) (60-90 mg/m(2)/day, day 1) and adriamycin (ADM) (20-40 mg/m(2)/day, day 1 or 2) was administered in 5 patients; CDDP (10-15 mg/m(2)/day, days 1-5) and epirubicin (epi-ADM) (10-15 mg/m(2)/day, days 1-5) was administered in 2 patients; and carboplatin (CBDCA) (200-400 mg/m(2)/day, day 1) and ADM (20-40 mg/m(2)/day, day 1 or 2) was administered in one patient. The responses were as follows: complete response in 2 patients (CDDP + ADM for lung metastasis, CDDP + epi-ADM for lymph node metastasis), partial response in 1 (CDDP + ADM for lymph node metastasis), stable disease in 2, and progressive disease in 3. A durable response was observed in 2 patients showing complete responses (58 and 112 months). The clinical effect of the combination of platinum and anthracycline for metastatic CSCC was limited despite the findings of two patients showing durable complete responses."}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nakamura,  Kenta"}], "nameIdentifiers": [{"nameIdentifier": "6921", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okuyama,  Ryuhei"}], "nameIdentifiers": [{"nameIdentifier": "6922", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saida,  Toshiaki"}], "nameIdentifiers": [{"nameIdentifier": "6923", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Uhara,  Hisashi"}], "nameIdentifiers": [{"nameIdentifier": "6924", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-24"}], "displaytype": "detail", "download_preview_message": "", "filename": "Platinum_anthracycline_therapy_advanced_cutaneous_squamous.pdf", "filesize": [{"value": "177.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1774000, "url": {"label": "Platinum_anthracycline_therapy_advanced_cutaneous_squamous.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/3767/files/Platinum_anthracycline_therapy_advanced_cutaneous_squamous.pdf"}, "version_id": "341fba41-3414-4418-8ca4-0f06980f1f70"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "Chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Cutaneous squamous cell carcinoma", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Skin cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Platinum", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Anthracycline", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma"}]}, "item_type_id": "6", "owner": "1", "path": ["461/462"], "permalink_uri": "http://hdl.handle.net/10091/17337", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_name_i18n": "\u516c\u958b\u65e5", "attribute_value": "2014-01-21"}, "publish_date": "2014-01-21", "publish_status": "0", "recid": "3767", "relation": {}, "relation_version_is_last": true, "title": ["Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma"], "weko_shared_id": 3}
  1. 050 医学部, 大学院医学系研究科 (Faculty&Graduate School of Medicine)
  2. 0501 学術論文 (Journal Articles)

Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma

http://hdl.handle.net/10091/17337
99cbc4e4-f56c-4b82-8b79-e330fdc97069
プレビュー
名前 / ファイル ライセンス Actions
Platinum_anthracycline_therapy_advanced_cutaneous_squamous.pdf Platinum_anthracycline_therapy_advanced_cutaneous_squamous.pdf (177.4 kB)
item type 学術雑誌論文 / Journal Article(1)
公開日 2014-01-21
タイトル
タイトル Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma
言語
言語 eng
キーワード
主題 Chemotherapy
キーワード
主題 Cutaneous squamous cell carcinoma
キーワード
主題 Skin cancer
キーワード
主題 Platinum
キーワード
主題 Anthracycline
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ journal article
著者 Nakamura, Kenta

× Nakamura, Kenta

WEKO 6921

Nakamura, Kenta

Search repository
Okuyama, Ryuhei

× Okuyama, Ryuhei

WEKO 6922

Okuyama, Ryuhei

Search repository
Saida, Toshiaki

× Saida, Toshiaki

WEKO 6923

Saida, Toshiaki

Search repository
Uhara, Hisashi

× Uhara, Hisashi

WEKO 6924

Uhara, Hisashi

Search repository
信州大学研究者総覧へのリンク
Okuyama, Ryuhei
http://soar-rd.shinshu-u.ac.jp/profile/ja.ZpfNHFSF.html
出版者
出版者 SPRINGER JAPAN KK
引用
内容記述タイプ Other
内容記述 INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 18(3):506-509 (2013)
書誌情報 INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY

巻 18, 号 3, p. 506-509, 発行日 2013-06
抄録
内容記述タイプ Abstract
内容記述 Because metastatic cutaneous squamous cell carcinoma (CSCC) is rare, standard chemotherapy has not been fully established. In Japan, combination platinum and anthracycline chemotherapy has been used for elderly patients with advanced CSCC because of its low toxicity. However, the clinical benefit of this therapy has not been fully examined. We retrospectively examined the response rate of combination platinum and anthracycline chemotherapy for metastatic CSCC. Eight patients received combination chemotherapy for metastatic lesions; there were lymph node lesions in 6 patients and skin and lung lesions in one patient each. The combination regimens were as follows: cisplatin (CDDP) (60-90 mg/m(2)/day, day 1) and adriamycin (ADM) (20-40 mg/m(2)/day, day 1 or 2) was administered in 5 patients; CDDP (10-15 mg/m(2)/day, days 1-5) and epirubicin (epi-ADM) (10-15 mg/m(2)/day, days 1-5) was administered in 2 patients; and carboplatin (CBDCA) (200-400 mg/m(2)/day, day 1) and ADM (20-40 mg/m(2)/day, day 1 or 2) was administered in one patient. The responses were as follows: complete response in 2 patients (CDDP + ADM for lung metastasis, CDDP + epi-ADM for lymph node metastasis), partial response in 1 (CDDP + ADM for lymph node metastasis), stable disease in 2, and progressive disease in 3. A durable response was observed in 2 patients showing complete responses (58 and 112 months). The clinical effect of the combination of platinum and anthracycline for metastatic CSCC was limited despite the findings of two patients showing durable complete responses.
資源タイプ(コンテンツの種類)
内容記述タイプ Other
内容記述 Article
ISSN
収録物識別子タイプ ISSN
収録物識別子 1341-9625
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AA11086579
PubMed
関連識別子
識別子タイプ PMID
関連識別子 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed&term=22534799
関連名称
関連名称 22534799
DOI
関連識別子
識別子タイプ DOI
関連識別子 http://dx.doi.org/10.1007/s10147-012-0411-y
関連名称
関連名称 10.1007/s10147-012-0411-y
権利
権利情報 The original publication is available at www.springerlink.com
著者版フラグ
値 author
WoS
Web of Science
http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000320456500022
Back
0
views
See details
Views

Versions

Ver.1 2021-03-01 09:07:03.061344
Show All versions

Share

Mendeley CiteULike Twitter Facebook Print Addthis

Cite as

Export

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by CERN Data Centre & Invenio


Powered by CERN Data Centre & Invenio